Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy
- 1 June 2006
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 54 (6) , 1003-1012
- https://doi.org/10.1016/j.jaad.2006.01.038
Abstract
No abstract availableKeywords
Funding Information
- Health Research Board
This publication has 45 references indexed in Scilit:
- Infliximab induction therapy for patients with severe plaque-type psoriasis: A randomized, double-blind, placebo-controlled trialJournal of the American Academy of Dermatology, 2004
- Dual functional roles of Tie-2/angiopoietin in TNF-α-mediated angiogenesisAmerican Journal of Physiology-Heart and Circulatory Physiology, 2004
- Antiangiogenic effects of anti–tumor necrosis factor α therapy with infliximab in psoriatic arthritisArthritis & Rheumatism, 2004
- Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing AgentNew England Journal of Medicine, 2001
- Treatment with anti-tumor necrosis factor α (TNF-α) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesionsJournal of the American Academy of Dermatology, 2000
- Tumor Necrosis Factor-α Upregulates Angiopoietin-2 in Human Umbilical Vein Endothelial CellsBiochemical and Biophysical Research Communications, 2000
- Tumor necrosis factor α antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitisPublished by Elsevier ,1999
- Immunolocalization of adhesion molecules in psoriatic arthritis, psoriatic and normal skinBritish Journal of Dermatology, 1995
- Requirement of Vascular Integrin α v β 3 for AngiogenesisScience, 1994
- Tumor necrosis factorJournal of the American Academy of Dermatology, 1991